IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma
- 208 Downloads
Hepatocellular carcinoma (HCC) is a growing concern all over the world. With the number of patients rising exponentially with each passing day, HCC is a problem that needs immediate attention. Currently, available treatment strategies focus on controlling the damage after the development of HCC. The options available from chemo- and radio-embolization to surgical resection and transplantation are not efficacious as required due to the complex nature of the disease. Liver regeneration and tissue healing are the subject of great interest today. Interleukin-22 (IL-22) is a cytokine with the ability to regenerate and therefore reverse the injuries caused by a wide range of agents. IL-22 acts via STAT molecule and controls the activity of a wide variety of cell survival and proliferation genes. Experimental data has given a positive insight into the role of IL-22 in inhibition of viral and alcohol-induced hepatocellular carcinoma. A further insight into the nature of IL-22 and the factors that can be manipulated in controlling the activity of IL-22 can help to counter the menace caused by the devastating effects of HCC.
KeywordsHepatocellular carcinoma IL-22 Liver regeneration
Muhammad Saalim and Saleha Resham performed the conception and design, acquisition of data, analysis and interpretation of data, and drafting of the article. Sobia Manzoor is the principal investigator and did the conception and design, analysis and interpretation of data, critical revision of the article, and final approval of the version to be published. Shahla Jaleel, Hassam Ahmad and Javed Ashraf participated in the critical revision of the article. Javed Ashraf, Muhammad Imran and Sidrah Naseem contributed in drafting the article.
Compliance with ethical standards
Conflicts of interest
- 1.Society AC. What are the key statistics about liver cancer? 2014. http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-what-is-key-statistics.
- 22.Okuhara S, Umemura T, Joshita S, Shibata S, Kimura T, Morita S et al. Serum levels of interleukin‐22 and hepatitis B core‐related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatology Research. 2014.Google Scholar
- 24.Ki SH, Park O, Zheng M, Morales‐Ibanez O, Kolls JK, Bataller R, et al. Interleukin‐22 treatment ameliorates alcoholic liver injury in a murine model of chronic‐binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology. 2010;52(4):1291–300.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Ashour TH. Therapy with interleukin-22 alleviates hepatic injury and hemostasis dysregulation in rat model of acute liver failure. Advances in hematology. 2014; 2014.Google Scholar
- 30.Kitaoka S, Shiota G, Kawasaki H. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C. Hepato-Gastroenterology. 2002;50(53):1569–74.Google Scholar
- 31.Huang Y, Hwang S, Chan C, Wu J, Chao Y, Chang F, et al. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua yi xue za zhi = Chinese medical journal. Free China ed. 1999;62(6):327–33.Google Scholar
- 32.Sato T, Asanuma Y, Masaki Y, Sato Y, Hatakeyama Y, Kusano T, et al. Changes in tumor necrosis factor-a and interleukin-1 beta production following liver surgery on cirrhotic patients. Hepato-Gastroenterology. 1995;43(11):1148–53.Google Scholar
- 33.Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld J-C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line pathways that are shared with and distinct from IL-10. J Biol Chem. 2002;277(37):33676–82.CrossRefPubMedGoogle Scholar
- 45.Zhang Y, Ji H, Liu Y, Shen X, Gao F, Fong C et al., editors. The immunomodulatory role of IL-22 in mouse liver ischemia and reperfusion injury (IRI): enhancement of autophagy by STAT3-c-myc signaling. American Journal of Transplantation; 2013: Wiley-Blackwell 111 River ST, Hoboken 07030-5774, NJ USA.Google Scholar
- 50.Zhang Z, Zhao J, Fu Y, Wang F-S. Increased IL-22-producing cells contribute to liver fibrosis through promoting Th17 migration in chronic HBV patients (P3363). The Journal of Immunology. 2013;190 (meeting abstracts 1):202.4.Google Scholar